Association of Multimorbidity with Cardiovascular Endpoints and Treatment Effectiveness in Patients 75 Years and Older with Atrial Fibrillation

J'Neka S. Claxton; Alanna M. Chamberlain; Pamela L. Lutsey; Lin Y. Chen; Richard F. MacLehose; Lindsay G.S. Bengtson; Alvaro Alonso

doi:10.1016/j.amjmed.2020.03.038

Association of Multimorbidity with Cardiovascular Endpoints and Treatment Effectiveness in Patients 75 Years and Older with Atrial Fibrillation

J'Neka S. Claxton, Alanna M. Chamberlain, Pamela L. Lutsey, Lin Y. Chen, Richard F. MacLehose, Lindsay G.S. Bengtson, Alvaro Alonso

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Background: The burden imposed by multimorbidity on outcomes and on the effectiveness of atrial fibrillation therapies in elderly adults with atrial fibrillation is unknown. Methods: Patients with nonvalvular atrial fibrillation ages ≥75 years in the MarketScan Medicare Supplemental database from 2007-2015. Prevalence of 14 chronic conditions at the time of atrial fibrillation diagnosis were obtained and classified as cardiometabolic or noncardiometabolic. Cox regression estimated the associations of the number and type of conditions with stroke, severe bleeding, and heart failure hospitalizations. Tests for interaction were assessed between atrial fibrillation treatments and multimorbidity. Results: Among 275,617 patients with atrial fibrillation (mean age 83 years, 51% women), the mean (SD) number of conditions per participant was 3.0 (2.1). Over a mean follow-up of 23 months, 7814 strokes, 13,622 severe bleeds, and 19,252 heart failure events occurred. After adjustment, an increase in the number of cardiometabolic conditions was associated with greater risk of stroke (hazard ratio [HR] 1.07; 95% confidence interval [CI], 1.05-1.10), severe bleeding (HR 1.09; 95% CI, 1.07-1.11), and heart failure (HR 1.19, 95% CI, 1.18-1.20). In contrast, number of noncardiometabolic conditions had weak or null associations with risk of cardiovascular endpoints. Overall, the effectiveness of atrial fibrillation treatment on stroke and heart failure were similar across multimorbidity status, but bleeding risk associated with atrial fibrillation treatments was higher in patients with overall and subgroup multimorbidity. Conclusion: Cardiometabolic multimorbidity was associated with worse outcomes and modified bleeding risk in atrial fibrillation patients. These findings underscore the impact of cardiometabolic conditions on atrial fibrillation outcomes and highlights the need to incorporate multimorbidity management in atrial fibrillation treatment guidelines.

Original language	English (US)
Pages (from-to)	e554-e567
Journal	American Journal of Medicine
Volume	133
Issue number	10
DOIs	https://doi.org/10.1016/j.amjmed.2020.03.038
State	Published - Oct 2020

Bibliographical note

Funding Information:
Funding: Research reported in this publication was supported by the National Heart, Lung, And Blood Institute and the National Institute on Aging of the National Institutes of Health under Award Numbers R01HL122200 , R21AG058445 , and K24HL148521 . The content is solely the responsibilities of the authors and does not necessarily represent the official views of the National Institutes of Health. This work was also supported by American Heart Association grant 16EIA26410001 .

Publisher Copyright:
© 2020

Keywords

Atrial fibrillation
Cardiovascular disease
Elderly
Multimorbidity

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/j.amjmed.2020.03.038

OpenUrl availability

Full text

Cite this

@article{16d8b282203c4fa78659a9b6c66dff61,

title = "Association of Multimorbidity with Cardiovascular Endpoints and Treatment Effectiveness in Patients 75 Years and Older with Atrial Fibrillation",

abstract = "Background: The burden imposed by multimorbidity on outcomes and on the effectiveness of atrial fibrillation therapies in elderly adults with atrial fibrillation is unknown. Methods: Patients with nonvalvular atrial fibrillation ages ≥75 years in the MarketScan Medicare Supplemental database from 2007-2015. Prevalence of 14 chronic conditions at the time of atrial fibrillation diagnosis were obtained and classified as cardiometabolic or noncardiometabolic. Cox regression estimated the associations of the number and type of conditions with stroke, severe bleeding, and heart failure hospitalizations. Tests for interaction were assessed between atrial fibrillation treatments and multimorbidity. Results: Among 275,617 patients with atrial fibrillation (mean age 83 years, 51% women), the mean (SD) number of conditions per participant was 3.0 (2.1). Over a mean follow-up of 23 months, 7814 strokes, 13,622 severe bleeds, and 19,252 heart failure events occurred. After adjustment, an increase in the number of cardiometabolic conditions was associated with greater risk of stroke (hazard ratio [HR] 1.07; 95% confidence interval [CI], 1.05-1.10), severe bleeding (HR 1.09; 95% CI, 1.07-1.11), and heart failure (HR 1.19, 95% CI, 1.18-1.20). In contrast, number of noncardiometabolic conditions had weak or null associations with risk of cardiovascular endpoints. Overall, the effectiveness of atrial fibrillation treatment on stroke and heart failure were similar across multimorbidity status, but bleeding risk associated with atrial fibrillation treatments was higher in patients with overall and subgroup multimorbidity. Conclusion: Cardiometabolic multimorbidity was associated with worse outcomes and modified bleeding risk in atrial fibrillation patients. These findings underscore the impact of cardiometabolic conditions on atrial fibrillation outcomes and highlights the need to incorporate multimorbidity management in atrial fibrillation treatment guidelines.",

keywords = "Atrial fibrillation, Cardiovascular disease, Elderly, Multimorbidity",

author = "Claxton, {J'Neka S.} and Chamberlain, {Alanna M.} and Lutsey, {Pamela L.} and Chen, {Lin Y.} and MacLehose, {Richard F.} and Bengtson, {Lindsay G.S.} and Alvaro Alonso",

note = "Funding Information: Funding: Research reported in this publication was supported by the National Heart, Lung, And Blood Institute and the National Institute on Aging of the National Institutes of Health under Award Numbers R01HL122200 , R21AG058445 , and K24HL148521 . The content is solely the responsibilities of the authors and does not necessarily represent the official views of the National Institutes of Health. This work was also supported by American Heart Association grant 16EIA26410001 . Publisher Copyright: {\textcopyright} 2020",

year = "2020",

month = oct,

doi = "10.1016/j.amjmed.2020.03.038",

language = "English (US)",

volume = "133",

pages = "e554--e567",

journal = "American Journal of Medicine",

issn = "0002-9343",

publisher = "Elsevier Inc.",

number = "10",

}

TY - JOUR

T1 - Association of Multimorbidity with Cardiovascular Endpoints and Treatment Effectiveness in Patients 75 Years and Older with Atrial Fibrillation

AU - Claxton, J'Neka S.

AU - Chamberlain, Alanna M.

AU - Lutsey, Pamela L.

AU - Chen, Lin Y.

AU - MacLehose, Richard F.

AU - Bengtson, Lindsay G.S.

AU - Alonso, Alvaro

N1 - Funding Information: Funding: Research reported in this publication was supported by the National Heart, Lung, And Blood Institute and the National Institute on Aging of the National Institutes of Health under Award Numbers R01HL122200 , R21AG058445 , and K24HL148521 . The content is solely the responsibilities of the authors and does not necessarily represent the official views of the National Institutes of Health. This work was also supported by American Heart Association grant 16EIA26410001 . Publisher Copyright: © 2020

PY - 2020/10

Y1 - 2020/10

N2 - Background: The burden imposed by multimorbidity on outcomes and on the effectiveness of atrial fibrillation therapies in elderly adults with atrial fibrillation is unknown. Methods: Patients with nonvalvular atrial fibrillation ages ≥75 years in the MarketScan Medicare Supplemental database from 2007-2015. Prevalence of 14 chronic conditions at the time of atrial fibrillation diagnosis were obtained and classified as cardiometabolic or noncardiometabolic. Cox regression estimated the associations of the number and type of conditions with stroke, severe bleeding, and heart failure hospitalizations. Tests for interaction were assessed between atrial fibrillation treatments and multimorbidity. Results: Among 275,617 patients with atrial fibrillation (mean age 83 years, 51% women), the mean (SD) number of conditions per participant was 3.0 (2.1). Over a mean follow-up of 23 months, 7814 strokes, 13,622 severe bleeds, and 19,252 heart failure events occurred. After adjustment, an increase in the number of cardiometabolic conditions was associated with greater risk of stroke (hazard ratio [HR] 1.07; 95% confidence interval [CI], 1.05-1.10), severe bleeding (HR 1.09; 95% CI, 1.07-1.11), and heart failure (HR 1.19, 95% CI, 1.18-1.20). In contrast, number of noncardiometabolic conditions had weak or null associations with risk of cardiovascular endpoints. Overall, the effectiveness of atrial fibrillation treatment on stroke and heart failure were similar across multimorbidity status, but bleeding risk associated with atrial fibrillation treatments was higher in patients with overall and subgroup multimorbidity. Conclusion: Cardiometabolic multimorbidity was associated with worse outcomes and modified bleeding risk in atrial fibrillation patients. These findings underscore the impact of cardiometabolic conditions on atrial fibrillation outcomes and highlights the need to incorporate multimorbidity management in atrial fibrillation treatment guidelines.

AB - Background: The burden imposed by multimorbidity on outcomes and on the effectiveness of atrial fibrillation therapies in elderly adults with atrial fibrillation is unknown. Methods: Patients with nonvalvular atrial fibrillation ages ≥75 years in the MarketScan Medicare Supplemental database from 2007-2015. Prevalence of 14 chronic conditions at the time of atrial fibrillation diagnosis were obtained and classified as cardiometabolic or noncardiometabolic. Cox regression estimated the associations of the number and type of conditions with stroke, severe bleeding, and heart failure hospitalizations. Tests for interaction were assessed between atrial fibrillation treatments and multimorbidity. Results: Among 275,617 patients with atrial fibrillation (mean age 83 years, 51% women), the mean (SD) number of conditions per participant was 3.0 (2.1). Over a mean follow-up of 23 months, 7814 strokes, 13,622 severe bleeds, and 19,252 heart failure events occurred. After adjustment, an increase in the number of cardiometabolic conditions was associated with greater risk of stroke (hazard ratio [HR] 1.07; 95% confidence interval [CI], 1.05-1.10), severe bleeding (HR 1.09; 95% CI, 1.07-1.11), and heart failure (HR 1.19, 95% CI, 1.18-1.20). In contrast, number of noncardiometabolic conditions had weak or null associations with risk of cardiovascular endpoints. Overall, the effectiveness of atrial fibrillation treatment on stroke and heart failure were similar across multimorbidity status, but bleeding risk associated with atrial fibrillation treatments was higher in patients with overall and subgroup multimorbidity. Conclusion: Cardiometabolic multimorbidity was associated with worse outcomes and modified bleeding risk in atrial fibrillation patients. These findings underscore the impact of cardiometabolic conditions on atrial fibrillation outcomes and highlights the need to incorporate multimorbidity management in atrial fibrillation treatment guidelines.

KW - Atrial fibrillation

KW - Cardiovascular disease

KW - Elderly

KW - Multimorbidity

UR - http://www.scopus.com/inward/record.url?scp=85085174374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85085174374&partnerID=8YFLogxK

U2 - 10.1016/j.amjmed.2020.03.038

DO - 10.1016/j.amjmed.2020.03.038

M3 - Article

C2 - 32320695

AN - SCOPUS:85085174374

SN - 0002-9343

VL - 133

SP - e554-e567

JO - American Journal of Medicine

JF - American Journal of Medicine

IS - 10

ER -

Association of Multimorbidity with Cardiovascular Endpoints and Treatment Effectiveness in Patients 75 Years and Older with Atrial Fibrillation

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this